Can we identify a preferred first-line strategy for sarcomatoid renal cell carcinoma? A network meta-analysis

Area of Science:

• Oncology
• Immunotherapy
• Clinical Trials

Background:

• Immune checkpoint inhibitor combinations are the current first-line standard for metastatic renal cell carcinoma.
• Sarcomatoid renal cell carcinoma (sRCC) presents a poor prognosis but demonstrates significant immunogenicity.
• Understanding optimal first-line treatments for sRCC is crucial due to its aggressive nature.

Purpose of the Study:

• To compare the efficacy of immune checkpoint inhibitor-based combinations against standard tyrosine kinase inhibitor monotherapy in sRCC.
• To identify the leading first-line treatment strategy for sarcomatoid renal cell carcinoma using network meta-analysis.
• To evaluate overall survival, progression-free survival, and objective response rates in sRCC patients.

Main Methods:

• A network meta-analysis was conducted on Phase III randomized controlled trials.
• Trials included patients with metastatic renal cell carcinoma, specifically reporting data for the sarcomatoid subtype (sRCC).
• Outcomes assessed included overall survival, progression-free survival, and objective response rate.

Main Results:

• Five trials involving 569 sRCC patients were analyzed.
• Nivolumab-cabozantinib ranked highest for overall survival (p-score = 88%) and progression-free survival (p-score = 81%).
• Atezolizumab-bevacizumab demonstrated the highest objective response rate (p-score = 80%).

Conclusions:

• Nivolumab-cabozantinib emerges as a potentially superior first-line treatment option for sarcomatoid renal cell carcinoma (sRCC).
• The findings suggest nivolumab-cabozantinib offers significant efficacy benefits for sRCC patients.
• Further research may confirm nivolumab-cabozantinib as the preferred first-line therapy for this specific renal cell carcinoma subtype.